NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00460265,Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer,https://clinicaltrials.gov/study/NCT00460265,SPECTRUM,COMPLETED,The purpose of this study is to determine the treatment effect of Panitumumab in combination with chemotherapy versus chemotherapy alone as first line therapy for metastatic and/or recurrent squamous cell carcinoma of the head and neck.,YES,Recurrent and/or Metastatic Head and Neck Cancer,DRUG: ARM 2|DRUG: ARM 1,"Overall Survival, Time from randomization to death, Upto 56 months","Overall Response Rate, An objective tumor response of complete or partial response per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 that was confirmed no less than 28 days after the criteria for response were first met. Complete response = disappearance of all target lesions and partial response = â‰¥30% reduction in lesion size., Every 6 weeks until disease progression, up to 56 months|Duration of Response, Time from the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) to disease progression using a modified version of the RECIST v1.0 (see protocol Appendix H)., Every 6 weeks until disease progression, up to 56 months|Time to Progression, Time from randomization date to date of disease progression using a modified version of the RECIST 1.0 (see protocol Appendix H), Every 6 weeks until disease progression, up to 56 months|Time to Response, Time from randomization date to the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) using a modified version of the RECIST v1.0., Every 6 weeks until disease progression, upto 56 months|Progression Free Survival, Time from randomization date to date of disease progression using a modified version of the RECIST v1.0 or death., Every 6 weeks until disease progression or deaths, upto 56 months",,Amgen,,ALL,"ADULT, OLDER_ADULT",PHASE3,658,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,20050251,2007-05,2010-05,2012-05,2007-04-13,2011-06-14,2014-03-07,,
